Fig. 15From: De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learninga Experimental binding pose of peptidomimetic inhibitor ML300 (PDB: 4MDS) and b docked pose of LaBECFar-4 on SARS-COV-2 Mpro. (PDB: 6W79). The amido acid residues are shown as bege sticks and the ligands as pink sticksBack to article page